Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated September 16, 2025, titled "Dr. Reddy's launches novel molecule Tegoprazan in India".
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Reddy's Laboratories has announced the launch of Tegoprazan, a novel molecule, in India. Tegoprazan is a potassium-competitive acid blocker used for treating acid-related gastrointestinal disorders. The launch marks the introduction of a new therapeutic option in the Indian market. The molecule has been developed or licensed to bring a differentiated treatment alternative for patients with conditions such as reflux disease and ulcers.
The launch adds a new revenue stream to Dr. Reddy's domestic portfolio and strengthens its gastroenterology segment, potentially boosting future growth if adoption picks up. The stock may see a positive reaction as it expands the company's innovative product offerings in India.